Related Experiment Video
Updated: Jul 18, 2025
05:30
Author Spotlight: Advancing the Analysis of Plasma Extracellular Vesicle Proteome for Cardiovascular Biomarker Studies
Published on: January 31, 2025
502
Extracellular Vesicles and Ischemic Cardiovascular Diseases
Yujiao Zhu1, Siqi Wang1, Xuerui Chen2
1Cardiac Regeneration and Ageing Lab, Institute of Cardiovascular Sciences, Shanghai Engineering Research Center of Organ Repair, School of Life Science, Shanghai University, Shanghai, China.
Advances in Experimental Medicine and Biology
|August 21, 2023
Summary
Extracellular vesicles (EVs) show promise for treating ischemic cardiovascular diseases and serve as biomarkers. EV-based therapy offers a biocompatible alternative to cell transplantation for cardiac repair.
Area of Science:
- Cardiovascular Biology
- Regenerative Medicine
- Biotechnology
Background:
- Ischemic cardiovascular diseases, marked by coronary artery obstruction, can lead to severe cardiac damage.
- Extracellular vesicles (EVs) are crucial for intercellular communication and cellular regulation.
- Current treatments like stem cell therapy face challenges such as tumorigenicity and immunogenicity.
Purpose of the Study:
- To summarize the cardioprotective roles of native and engineered EVs.
- To explore the potential of EVs as biomarkers for ischemic cardiovascular diseases.
- To highlight EV-based therapy as a regenerative strategy for cardiac repair.
Main Methods:
- Review of existing literature on extracellular vesicles in cardiovascular contexts.
- Analysis of studies detailing the composition and function of EVs from various cell types.
- Evaluation of diagnostic and therapeutic applications of EVs in ischemic heart disease.
Main Results:
- EVs facilitate paracrine signaling involved in cardiac homeostasis and disease pathophysiology.
- Native and bioengineered EVs from diverse cells (stem cells, cardiomyocytes, etc.) exhibit cardioprotective functions.
- Circulating EVs can serve as noninvasive biomarkers for early clinical diagnosis of ischemic cardiovascular disease.
Conclusions:
- EVs represent a promising cell-free therapeutic approach for cardiac repair and regeneration.
- EVs offer a biocompatible and potentially safer alternative to direct cell-based therapies.
- The diagnostic potential of EVs as biomarkers for ischemic cardiovascular diseases is significant.
Related Concept Videos
01:17Ischemic Heart Disease: Overview
1.3K
Ischemic heart disease occurs when the heart's blood supply dwindles, causing an ominous lack of oxygen and nutrients. This deficiency, stemming from reduced or obstructed blood flow, spells danger, leading to heart muscle damage and dysfunction.
Atherosclerosis, the primary malefactor, orchestrates this dangerous condition. It manifests as the accumulation of fatty deposits, akin to insidious plaques, within arterial walls. As time elapses, these plaques metamorphose, hardening and...
Atherosclerosis, the primary malefactor, orchestrates this dangerous condition. It manifests as the accumulation of fatty deposits, akin to insidious plaques, within arterial walls. As time elapses, these plaques metamorphose, hardening and...
1.3K
01:36Overview of Exosomes
2.7K
Exosomes are stable, lipid bilayer-enclosed vesicles capable of crossing biological barriers. They can carry a wide range of molecules required for intercellular communication. Once exosomes are released from the cell where they originated, they enter a recipient cell through various pathways such as fusion, receptor-mediated endocytosis, macropinocytosis, and phagocytosis.
Stahl et al. discovered exosomes in 1983, but the exosomes were initially considered waste products released from the...
Stahl et al. discovered exosomes in 1983, but the exosomes were initially considered waste products released from the...
2.7K
01:26Coronary Artery Disease II: Pathophysiology
12
Coronary Artery Disease (CAD) originates from a series of events that impair the function of coronary arteries, the blood vessels responsible for delivering oxygen-rich blood to the heart muscle. The pathophysiology of CAD is closely linked to atherosclerosis, a chronic inflammatory and lipid-driven condition affecting the vascular endothelium.1. Endothelial DamageThe process begins with damage to the vascular endothelium, which serves as a protective barrier between the blood and the vessel...
12
01:19Acute Coronary Syndrome II: Pathophysiology and Clinical Manifestations
20
The pathophysiology of Acute Coronary Syndrome [ACD] involves several key processes:The main underlying cause of ACD is atherosclerosis, a chronic inflammatory disease characterized by the buildup of lipid-laden plaques within the coronary arteries.As the atherosclerotic plaque grows in the coronary artery, it may become unstable due to the formation of a lipid-rich core and a thin fibrous cap. Inflammatory cells within the plaque, such as macrophages, secrete enzymes that degrade the...
20
01:18Cardiovascular Drugs: Classification based on Therapeutic Indications
2.9K
Cardiovascular diseases, encompassing a range of conditions, can significantly affect the heart's operations and the overall circulatory system. These conditions impair the heart's ability to pump blood, leading to a deficit in oxygen supply to crucial organs. Anomalies in the heart's electrical system, known as arrhythmias, can cause heartbeats to accelerate or slow down. Usually, heart rates increase during physical activity and decrease while resting or sleeping. However,...
2.9K
01:38Intralumenal Vesicles and Multivesicular Bodies
3.6K
Intraluminal vesicles (ILVs) are small vesicles 50-80 nm in diameter formed during the maturation of early endosomes. A specialized endosome containing numerous ILVs is called a multivesicular body (MVB). ILVs contain internalized molecules such as antigens, nucleic acids, proteins, and metabolites. Some of these molecules are released from the MVBs inside exosomes and are transported to other cells. Other MVBs contain molecules that are retained in the ILVs and are later degraded within the...
3.6K